^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

    Excerpt:
    ...del(17p13), t(4;14) with ISS II or III, t(14;16), t(14;20) and chromosome 1 abnormalities by FISH....
    Trial ID:
    NCT02308280
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

    Published date:
    11/04/2021
    Excerpt:
    CONTRADICTORY EVIDENCE:...we conducted this retrospective real-world study on efficacy and safety of the mainstream maintenance regimens in non-transplant NDMM patients-thalidomide (T-MT), lenalidomide (L-MT) and bortezomib (B-MT)....Only a few patients with 17p- in T-MT and B-MT, yet also presented remarkably inferior PFS (7.0m vs 21.0m, p=0.011) and OS (32.0m vs 81.0m, p=0.001) with thalidomide....In B-MT, PFS (30.8m vs NR, p=0.99) was similar, though median OS was not reached, inferior tendency was observed (p= 0.04).
    DOI:
    https://doi.org/10.1182/blood-2021-149502
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

    Published date:
    11/06/2019
    Excerpt:
    In conclusion, our studies demonstrate the clinical benefits of BTZ-induced ICD in MM; and that loss-of-function of GABARAP, particularly in HR patients with 17p deletion, abrogates induction of antitumor immunity after drug exposure.
    DOI:
    https://doi.org/10.1182/blood-2019-126584
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Leuk Res
    Title:

    Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma

    Excerpt:
    ...patients with del(13q), del(17p), t(4;14) and high-risk genetic abnormalities have lower expression levels of miR-33b compared to patients without those of abnormalities (p = 0.032, 0.018, 0.034, 0.005). Survival analysis showed patients with miR 33b low expression had significantly shortened PFS (p = 0.016) and OS (p = 0.033) and might be associated with drug resistance to bortezomib-based treatment....Our data suggest that down-regulated miR 33b might be a novel predictor associated with disease progression and poor prognosis in MM.
    DOI:
    https://doi.org/10.1016/j.leukres.2015.04.010